EP PerMed - the1st Twinning call (2026)

The EP PerMed Twinning Call (2026) is a funding opportunity designed to facilitate the implementation of personalised medicine solutions across EU Member States and associated countries. This program operates under the European Partnership for Personalised Medicine and aims to foster peer-to-peer exchanges between health and care providers.

Eligible applicants are local, regional, and national health providers legally established in an EU Member State or Horizon Europe-associated countries. The call specifically seeks two types of organizations: Twinning Donor organizations with a mature personalised medicine solution available for transfer, and Twinning Receiver organizations seeking to adopt these solutions.

The funding mechanism is structured as grants provided through lump sum contracts, allowing a maximum of €50,000 per Twinning partnership. Upon signing the grant agreement, recipients receive 50% pre-payment, with the remainder disbursed once a final activity report is approved. The funding aims to support activities such as hosting meetings, travel expenses, and fees for professional services, focusing strictly on operational costs rather than product development.

Consortium participation is required, mandating the formation of a transnational group consisting of one Donor and one to two Receiver organizations from at least two EU Member States or countries associated with Horizon Europe.

The project should focus on established and mature personalised medicine solutions, with a Technology Readiness Level of 9 if technological. The call emphasizes adoption and implementation rather than research and development.

Significant dates include the call's opening on 10 December 2025 with a submission deadline on 26 February 2026. After submissions, there will be eligibility checks, online pitching sessions in April 2026, and funding decisions made in May 2026. Successful partnerships are expected to conduct their activities over 6 to 12 months.

Specific evaluation criteria include excellence, impact, implementation feasibility, and the quality of pitches, requiring a minimum score of 70/100 for funding consideration. No co-funding is necessary, simplifying financial commitments for recipients.

Overall, the EP PerMed Twinning Call prioritizes the exchange of knowledge and experiences in personalised medicine, aiming to enhance healthcare systems across Europe through collaborative, structured partnerships.

The EP PerMed 1st Twinning Call (2026) is a funding opportunity designed to accelerate the implementation of personalised medicine (PM) solutions or approaches across different countries through peer-to-peer exchanges. The call operates under the European Partnership for Personalised Medicine (EP PerMed) framework.

Key Details:

Project Acronym: EP PerMed
Full Name of the EU Funded Project: European Partnership for Personalised Medicine
Grant Agreement Number: 101137129
Topic: HORIZON-HLTH-2023-CARE-08-01 - European Partnership on Personalised Medicine
Total Funding Available: 150,000 EUR

Timeline:

Online Matchmaking Period: 13 October 2025 – 26 February 2026
Call for Proposals Submission Opening: 10 December 2025
Call Information Webinar: 17 December 2025 at 12:00 CET
Online Matchmaking Event: 15 January 2026
Deadline for Proposals Submission: 26 February 2026 at 16:00 CET (Brussels time)
Notification of Eligibility Check Outcome and Invite to Online Pitching Sessions: 23 March 2026
Online Pitching Sessions: 14 – 21 April 2026
Final Results Notification: 06 May 2026
Kick-off Meeting: Week beginning 08 June 2026

Twinning Concept:

The call utilizes a ‘Twinning’ model, which involves a structured partnership between a ‘Twinning Donor’ and a ‘Twinning Receiver’. The Twinning Donor shares expertise in an innovative PM solution or approach with the Twinning Receiver. The primary goal is to implement the shared solution or approach within the Twinning Receiver's institution, organization, or company.

Funding Details:

Funding Amount: Up to 50,000 EUR per Twinning partnership.
Eligible Activities: Funding can be used for activities that facilitate the exchange of PM solutions or approaches and build capacities and capabilities of the participating parties. This includes hosting meetings or working groups, covering travel expenses, and paying for professional services.
Project Duration: Twinning partnerships should last between 6 and 12 months.
Consortium Size: Each Twinning partnership should include at least two and up to three institutions. One institution acts as the Donor, and up to two institutions act as Receivers.
Funding Mechanism: Funding is provided through lump sum contracts, with a 50% pre-payment and the remaining 50% disbursed upon approval of the final activity report.

Expected Outcomes for Twinning Receiver Institutions:

Initiate implementation of a defined PM solution or approach with support.
Adapt a PM solution or approach.
Partially adopt a PM solution or approach.
Fully adopt or acquire a solution or approach.

Application Process:

Submission Platform: Applications must be submitted via the EIT Health Application Platform: https://apply.eithealth.eu/s_Login.jsp.
Application Instructions: Follow the instructions on the platform to complete account registration.
Support: For questions, refer to the “Guide for applicants” or contact smartsimple@eithealth.eu.

Main Steps in the Process:

Application Submission: Applicants submit proposals through the EIT Health Smart Simple application platform, forming a consortium with one Twinning Donor and up to two Twinning Receiver organizations.
Eligibility Check: Applications are reviewed against the general and specific conditions outlined in the Twinning call document. This check determines whether the proposal meets the requirements and can proceed to the next evaluation stage.
Online Pitching: Eligible applications are invited to present their proposals at an online pitch session between 14-21 April 2026. The pitching process includes a 15-minute presentation followed by a 20-minute Q&A session with a panel of independent experts. Each proposal is evaluated by three external independent evaluators.
Funding Decision: Projects are ranked by evaluation score, and the highest-ranked projects are selected for funding. A minimum score of 70/100 is required for funding consideration.
Twinning Exchange: Successful consortia have 12 months to carry out the Twinning activities.
Interim Report: Consortia submit an interim report after 6 months to verify ongoing activities and progress toward project objectives.
Final Report: Consortia submit a final activity report after 12 months to verify completion of the activity and achievement of project objectives.

Eligibility Criteria:

General Requirements:

Submission Deadline: Proposals must be submitted by 26 February 2026 at 16:00 CET.
Language: Applications and Twinning activities must be conducted in English. The Project Grant Agreement (PGA) must be signed in its English version.
Funding Limit: Applications can request a maximum of 50,000 EUR, including overheads.
Templates: Applicants must use and upload the correct templates provided in the application platform.
Legal Registration: All applicants must be legally registered in a Horizon Europe country or associated country.
Technology Readiness: The PM solution or approach must be mature for implementation, with technological solutions at TRL 9 and CE-marked if required.

Consortium Requirements:

Composition: Each consortium must include one Donor organization and at least one, but no more than two, Receiver organizations.
Transnationality: The consortium must be transnational, involving a minimum of two and a maximum of three organizations legally registered in at least two different EU Member State countries or countries associated with Horizon Europe.
Independence: Consortium members must be legally and financially independent of each other.
Applicant Categories:
Twinning Donor organizations: Local, regional, and national health and care providers established in an EU Member State or country associated with Horizon Europe, with a PM solution or approach available for transfer.
Twinning Receiver organizations: Local, regional, and national health and care providers established in an EU Member State or country associated with Horizon Europe, wishing to adopt the Twinning Donor organization’s PM solution or approach.
Completeness: The consortium must be fully formed at the time of submission.

Eligible Costs and Project Duration:

Eligible Activities: Funding can cover hosting meetings or working groups, travel expenses, and fees for professional services.
Ineligible Costs: Costs for further development of PM solutions, devices, instruments, and equipment are not eligible.
Project Timeline: Funding supports the Twinning activity up to the submission of the final activity report, which must be delivered no later than 6 May 2027.

Evaluation Process and Criteria:

Single Proposal Submission: The selection process involves a single proposal submission via the EIT Health Smart Simple application platform.
Independent Evaluation: Applications are reviewed and evaluated by an independent panel of experts, scored on a scale of 0 to 100.

Evaluation Criteria:

Excellence (35%): Alignment with the Call scope, objectives, and intended outcomes.
Impact (40%): Clear value of benefit for the Twinning Receiver(s’) patients, citizens, organization, and/or healthcare system(s).
Implementation (15%): Completeness and feasibility of the work plan, and the team’s capacity/expertise to deliver the project.
Pitch Quality (10%): Clarity and conciseness of the online pitch.
Scoring: Each proposal is evaluated by three external program evaluators, and the final score is the average of their scores.
Cost Plan: Pre-selected projects must provide a detailed cost plan. Suggestions will be provided in case of imbalance and should be considered before signing the contract.

Redress Procedure:

Appeal Submission: Applicants can appeal against the final award decision if they suspect a breach in the evaluation and selection procedures. Appeals must be submitted to EIT Health via email (appeals@eithealth.eu) within seven calendar days of the outcome notification.
Admissibility Conditions:
The appeal must be submitted by the team to which the appeal relates.
Only one appeal per proposal will be considered.
The appeal must be submitted via email within seven calendar days of the outcome notification email.
Required Information: The appeal must include the name of the Call for Proposals, the proposal acronym, the title of the proposal, and a description of the alleged shortcomings of the evaluation procedure.
Grounds for Appeal: The appeal must demonstrate a procedural irregularity, factual error, manifest error of assessment, misuse of powers, or a conflict of interests.
Procedure:
Acknowledgement: EIT Health will send an acknowledgement of receipt within seven calendar days.
Decision Communication: The decision on the appeal will be communicated to the appellant within 2 weeks from the deadline for submitting appeals.

Further Information:

Call Details: All information concerning the EP PerMed 1st Twinning call (2026), including the call text outlining the aims and scope of the call, can be found at www.eppermed.eu/twinning-2026/.

Online Webinar and Call Contact Information:

Matchmaking Platform: Open from 13 October 2025 to 26 February 2026. Join the platform to list your organization as a Twinning Donor or Twinning Receiver and find twinning partners: https://www.b2match.com/e/online-matchmaking-ep-permed-twinning.
Call Information Webinar: 17 December 2025, 12:00 to 13:00 CET. Register to join the online webinar to learn more about the call and ask questions.
Online Matchmaking Event: 15 January 2026, 12:00 to 14:00 CET. Register to join the online matchmaking event to find twinning partners.

In summary, the EP PerMed Twinning Call is a funding initiative aimed at fostering collaboration and knowledge transfer in the field of personalised medicine. It provides financial support for partnerships between institutions with established PM solutions (Donors) and those seeking to adopt or adapt such solutions (Receivers). The call encourages transnational collaboration and offers a structured framework for implementing innovative PM approaches across different healthcare systems in Europe. The application process involves a single-stage submission, followed by eligibility checks, online pitching sessions, and a comprehensive evaluation based on excellence, impact, implementation, and pitch quality. Successful projects receive funding to facilitate the twinning exchange and contribute to the broader adoption of personalised medicine practices.

Eligible Applicant Types: The eligible applicant types are local, regional, and national health and care providers established in an EU Member State or country associated with Horizon Europe. Specifically, there are two categories: Twinning Donor organizations with a PM solution or approach available for transfer, and Twinning Receiver organizations that wish to adopt the Twinning Donor organization’s PM solution or approach.

Funding Type: The primary financial mechanism is a grant, provided through lump sum contracts. 50% of the funding is provided as pre-payment, and the remaining 50% is disbursed upon approval of the final activity report.

Consortium Requirement: A consortium is required. The consortium must include one Donor organization and at least one, but not more than two Receiver organizations.

Beneficiary Scope (Geographic Eligibility): Applicants must be legally registered in a Horizon Europe country or associated country. The consortium must be transnational, involving a minimum of two and a maximum of three organizations legally registered in at least two different EU Member State countries or countries associated to Horizon Europe.

Target Sector: The program targets the health sector, specifically personalized medicine (PM).

Mentioned Countries: The opportunity is open to EU Member States and countries associated with Horizon Europe. No specific countries are explicitly mentioned, but the requirement for transnational consortia implies involvement of at least two different EU Member States or associated countries.

Project Stage: The PM solution or approach must be mature for implementation. For technological solutions, this means Technology Readiness Level (TRL) 9 and CE-marked if required.

Funding Amount: Up to 50,000 EUR per Twinning partnership. The total funding available for the call is 150,000 EUR.

Application Type: The application type is an open call with a single-stage submission process.

Nature of Support: Beneficiaries will receive money in the form of a grant.

Application Stages: The application process involves several stages: application submission, eligibility check, online pitching, funding decision, twinning exchange, interim report, and final report.

Success Rates: The success rates are not explicitly mentioned, but only projects that receive a final score of at least 70/100 will be considered for funding.

Co-funding Requirement: The information does not explicitly state a co-funding requirement.

Summary:

The EP PerMed Twinning Call is an initiative under the European Partnership for Personalised Medicine, designed to accelerate the implementation of personalized medicine solutions across different regions. It operates through a "twinning" model, where an organization with an innovative PM solution (the Donor) partners with another organization (the Receiver) to facilitate the adoption and implementation of that solution. The call provides grants of up to 50,000 EUR per twinning partnership to support activities that enable the exchange of knowledge and build capacities.

To be eligible, applicants must form a transnational consortium of two to three organizations, including one Donor and one or two Receiver organizations, all legally registered in EU Member States or countries associated with Horizon Europe. The Donor organization must have a mature PM solution ready for implementation (TRL 9 if technological, and CE-marked if required), while the Receiver organization(s) should be willing to adopt this solution.

The application process involves a single-stage submission via the EIT Health application platform, followed by an eligibility check and an online pitching session. Proposals are evaluated based on excellence, impact, implementation, and pitch quality. Successful projects receive funding in lump sums, with an initial 50% pre-payment and the remaining 50% upon completion of the project and approval of the final report. The twinning activities are expected to last for 12 months. The call aims to foster the adoption of personalized medicine solutions, improve healthcare systems, and benefit patients and citizens across Europe.